CRISPR THERAPEUTICS AG (CRSP) Stock Analyst Ratings
USA - NASDAQ:CRSP - CH0334081137 - Common Stock
63.99 USD
+2.89 (+4.73%)
64.364 USD
+0.37 (+0.58%)
ChartMill assigns a Buy % Consensus number of 77% to CRSP. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 82.34. This target is 28.67% above the current price.
CRSP was analyzed by 36 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about CRSP.
In the previous month the buy percentage consensus was at a similar level.
CRSP was analyzed by 36 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-17 | B of A Securities | Maintains | Buy -> Buy |
| 2025-10-10 | Needham | Reiterate | Buy -> Buy |
| 2025-09-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-18 | JP Morgan | Initiate | Overweight |
| 2025-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-06 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-05 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-07-22 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-08 | Needham | Reiterate | Buy -> Buy |
| 2025-06-27 | Clear Street | Downgrade | Buy -> Hold |
| 2025-06-27 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-06-27 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-06-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-26 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-06-26 | Needham | Reiterate | Buy -> Buy |
| 2025-05-21 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-05-20 | Needham | Reiterate | Buy -> Buy |
| 2025-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-09 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-08 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-05-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-07 | Needham | Maintains | Buy -> Buy |
| 2025-04-09 | Needham | Reiterate | Buy -> Buy |
| 2025-02-19 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2025-02-18 | Citigroup | Maintains | Buy -> Buy |
| 2025-02-14 | Evercore ISI Group | Upgrade | In-Line -> Outperform |
| 2025-02-14 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2025-02-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-13 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
CRISPR THERAPEUTICS AG / CRSP FAQ
Can you provide the average price target for CRISPR THERAPEUTICS AG stock?
36 analysts have analysed CRSP and the average price target is 82.34 USD. This implies a price increase of 28.67% is expected in the next year compared to the current price of 63.99.
How do analysts rate CRISPR THERAPEUTICS AG (CRSP)?
The consensus rating for CRISPR THERAPEUTICS AG (CRSP) is 76.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.